Baird R W cut shares of Leap Therapeutics (NASDAQ:LPTX - Free Report) from a strong-buy rating to a hold rating in a research report released on Wednesday,Zacks.com reports.
A number of other analysts also recently issued reports on the stock. HC Wainwright downgraded shares of Leap Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday. Robert W. Baird cut shares of Leap Therapeutics from an "outperform" rating to a "neutral" rating and lowered their price target for the stock from $9.00 to $1.25 in a report on Wednesday.
View Our Latest Research Report on Leap Therapeutics
Leap Therapeutics Stock Down 9.0 %
LPTX stock traded down $0.05 during midday trading on Wednesday, hitting $0.52. The company's stock had a trading volume of 1,903,680 shares, compared to its average volume of 1,396,965. Leap Therapeutics has a 1 year low of $0.51 and a 1 year high of $4.79. The stock has a market cap of $19.93 million, a price-to-earnings ratio of -0.27 and a beta of 0.17. The stock's 50-day moving average price is $2.82 and its 200 day moving average price is $2.75.
Institutional Trading of Leap Therapeutics
Institutional investors have recently modified their holdings of the business. Valence8 US LP bought a new stake in Leap Therapeutics during the 3rd quarter valued at $48,000. HighTower Advisors LLC purchased a new position in Leap Therapeutics during the 3rd quarter valued at about $65,000. HB Wealth Management LLC increased its holdings in Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company's stock worth $150,000 after acquiring an additional 26,150 shares during the period. Marshall Wace LLP raised its position in shares of Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company's stock worth $156,000 after buying an additional 58,094 shares in the last quarter. Finally, Exome Asset Management LLC bought a new position in Leap Therapeutics in the 3rd quarter worth about $264,000. 30.46% of the stock is currently owned by hedge funds and other institutional investors.
About Leap Therapeutics
(
Get Free Report)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Featured Articles
Before you consider Leap Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Leap Therapeutics wasn't on the list.
While Leap Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
